Doug Mendenhall, Ph.D. has been named interim head of Patheon’s Pharmaceutical Development Services Unit and will also serve as interim chief scientific officer. Dr. Mendenhall is working under contract until a permanent president is named, but will be retained as an advisor to the company on an as-needed basis. Dr. Mendenhall is a 35-year veteran in the pharmaceutical industry, having held executive positions at Abbott, GlaxoSmithKline and most recently, Merck. He has spent his career...